יחס חוב לטווח קצר להון עצמי: Cognition Therapeutics (CGTX)

Cognition Therapeutics (CGTX) develops treatments against neuronal degeneration without having any products currently on the market. The business relies on external financing, and its metric stands at 0.01. Historical price action on GURU.Markets links these financial aspects to the implementation of IT systems for protein analysis and test automation. However, global political fragmentation and sanctions complicate component logistics and the conduct of international research.

This metric assesses the extent of the company's reliance on short-term borrowings relative to its equity. By analyzing the short-term debt-to-equity ratio, an investor determines liquidity risk and the business's ability to service obligations due within one year. This chart reflects the balance between financial leverage and asset stability. For Cognition Therapeutics (CGTX), a low debt level is critical to ensuring the long-term development of Alzheimer's disease drugs.